Chinese CDMO and API manufacturer providing contract development/manufacturing services to global and domestic pharma companies.
Chinese CDMO and API manufacturer providing contract development/manufacturing services to global and domestic pharma companies.
Earns from multi-year contract manufacturing for global drugmakers, making intermediates and the active ingredient for products still in development, so revenue scales as those drugs move to launch; routine API sales of established products are a separate line. Audits by the US and European regulators underpin customers' trust.
In one line: A Chinese WuXi STA/Lonza (CDMO).
Moat: narrow (scale, regulatory licence, customer qualification). FDA/EU-audited manufacturing capacity and long-standing CDMO relationships with global pharma.
Headquarters: Taizhou, Zhejiang, China · Employees: 4,791
Size Zhejiang Jiuzhou Pharmaceutical (603456.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.03B, the 1154th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥15.48 on 18 Nov 2026.
Performance Over six months the shares gained 19.2%, against -5.5% for the median peer and -20.0% for the China market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue fell 1.3% over the last twelve months (peer median +10.7%); the operating margin is 14.1% (peer median 22.2%).
Valuation It trades at 16.9× forward earnings against a peer median of 18.1× (9th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -14 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.5 points above its cost of capital (7.6% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥5.28B | CN¥5.47B | CN¥5.13B | CN¥5.50B | CN¥5.43B |
| Revenue growth | — | +7% | -7% | +1% | — |
| Gross profit | CN¥2.13B | CN¥1.87B | CN¥1.60B | CN¥1.94B | CN¥1.77B |
| EBITDA | n/a | CN¥1.48B | CN¥1.11B | CN¥1.47B | CN¥1.38B |
| Net income | CN¥599M | CN¥730M | CN¥606M | CN¥1.03B | CN¥921M |
| Free cash flow | CN¥842M | CN¥1.17B | CN¥105M | CN¥431M | CN¥517M |
| Capital expenditure | CN¥563M | CN¥660M | CN¥889M | CN¥929M | CN¥714M |
| Total debt | CN¥240M | CN¥195M | CN¥705M | CN¥728M | CN¥820M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | $2.03B | +19% | -1% | 14% | 16.9× | 1.7% |
| Wuxi Apptec 2359.HK | $64.1B | +51% | +38% | 44% | 19.5× | 8.4% |
| Apeloa Pharmaceutical 000739.SZ | $3.37B | +17% | -16% | 10% | 22.9× | 4.7% |
| Asymchem Laboratories (Tianjin) 002821.SZ | $7.27B | +20% | +18% | 17% | 37.4× | n/a |
| Porton Pharma Solutions 300363.SZ | $1.66B | +37% | +6% | -2% | n/a | 2.1% |
| Zhejiang Huahai Pharmaceutical 600521.SS | $3.61B | 0% | +10% | 12% | 20.1× | 6.4% |
| Zhejiang Medicine 600216.SS | $1.51B | -26% | -6% | 7% | 11.5× | -7.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603456.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.9% | +2.7% | 5th lowest of 21 |
| 6-month return | +19.2% | -5.5% | 4th highest of 21 |
| Distance from 52-week high | -30.4% | -26.0% | 8th lowest of 21 |
| Revenue growth (TTM) | -1.3% | +10.7% | 4th lowest of 20 |
| Operating margin | 14.1% | 22.2% | 7th lowest of 20 |
| Forward P/E | 16.9× | 18.1× | 9th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 1.7% | 2.2% | 8th least demanding of 15 |
| Growth delivered (Del g) | +15.7% | +12.3% | 6th highest of 15 |
| Hurdle (Req g minus delivered) | -14.0 pp | -10.3 pp | 6th least demanding of 15 |
| ROIC minus cost of capital | +2.5 pp | +1.6 pp | 10th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.03B | +19% | -1% | 14% | 16.9× | 1.7% | +15.7% |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.03B | -3% | +9% | 14% | 25.9× | 5.1% | +6.4% |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.02B | -45% | 0% | -47% | n/a | n/a | n/a |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.04B | +9% | +5% | 22% | 15.9× | -4.7% | +10.6% |
| Hanall Biopharma 009420.KS | South Korea | $2.01B | +12% | +5% | 3% | n/a | n/a | n/a |
| InnoCare Pharma 9969.HK | Hong Kong | $2.01B | -10% | +146% | 35% | 32.2× | -2.0% | +341.1% |
| Eris Lifesciences ERIS.NS | India | $1.98B | 0% | +11% | 26% | 27.9× | 26.3% | +20.9% |
| Haw Par H02.SI | Singapore | $2.08B | -25% | -13% | 30% | 11.9× | 3.2% | +15.7% |
| PharmaResearch 214450.KS | South Korea | $2.10B | -24% | +29% | 37% | 15.4× | -11.0% | +37.6% |
| Biohaven BHVN | United States | $1.95B | +46% | n/a | n/a | n/a | n/a | n/a |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.95B | -14% | +11% | 6% | 44.6× | n/a | n/a |
| Harmony Biosciences HRMY | United States | $1.94B | +6% | +20% | 22% | 8.6× | -10.5% | +40.3% |
| Jinyu Bio-Technology 600201.SS | China | $1.93B | -21% | +22% | 10% | 59.0× | 23.4% | -2.5% |
| Tsumura & 4540.T | Japan | $1.93B | +6% | +13% | 18% | 10.4× | n/a | n/a |
| Grand Pharmaceutical 0512.HK | Hong Kong | $1.93B | -25% | +7% | 13% | 9.4× | 1.2% | +14.1% |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 54.3× | n/a | n/a |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% | +2.4% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 18.1× | 8.0% | +9.3% |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 12.5× | -1.2% | +16.7% |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.19B | +14% | -7% | 15% | 15.0× | -9.7% | -1.5% |